International Journal of Hypertension [154] N. M. Kaplan, “Resistant hypertension,” Journal of Hypertension, vol. 23, no. 8, pp. 1441–1444, 2005. [155] V. M. Campese, N. Mitra, and D. Sandee, “Hypertension in renal parenchymal disease: why is it so resistant to treatment?” Kidney International, vol. 69, no. 6, pp. 967–973, 2006. [156] G. M. Singer, M. Izhar, and H. R. Black, “Goal-oriented hypertension management: translating clinical trials to practice,” Hypertension, vol. 40, no. 4, pp. 464–469, 2002. [157] J. P. Casas, W. Chua, S. Loukogeorgakis et al., “Eﬀect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis,” Lancet, vol. 366, no. 9502, pp. 2026–2033, 2005. [158] ONTARGET Investigators, “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, pp. 1547–1559, 2008. [159] J. F. Mann, R. E. Schmieder, M. McQueen et al., “Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial,” Lancet, vol. 372, no. 9638, pp. 547–553, 2008. [160] P. A. Saraﬁdis and G. L. Bakris, “Renin-angiotensin blockade and kidney disease,” Lancet, vol. 372, no. 9638, pp. 511–512, 2008. [161] R. D. Saﬁan and S. C. Textor, “Renal-artery stenosis,” New England Journal of Medicine, vol. 344, no. 6, pp. 431–442, 2001. [162] C. J. White, “Catheter-based therapy for atherosclerotic renal artery stenosis,” Circulation, vol. 113, no. 11, pp. 1464–1473, 2006. [163] R. A. Aqel, G. J. Zoghbi, S. A. Baldwin et al., “Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization,” Journal of Hypertension, vol. 21, no. 6, pp. 1157–1162, 2003. [164] R. T. Tumelero, N. T. Duda, A. P. Tognon, and M. Thiesen, “Prevalence of renal artery stenosis in 1,656 patients who have undergone cardiac catheterization,” Arquivos Brasileiros de Cardiologia, vol. 87, no. 3, pp. 213–253, 2006. [165] G. H. Anderson Jr., N. Blakeman, and D. H. P. Streeten, “The eﬀect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients,” Journal of Hypertension, vol. 12, no. 5, pp. 609–615, 1994. [166] J. J. Crowley, R. M. Santos, R. H. Peter et al., “Progression of renal artery stenosis in patients undergoing cardiac catheterization,” American Heart Journal, vol. 136, no. 5, pp. 913–918, 1998. [167] T. Leiner, M. W. de Haan, P. J. Nelemans, J. M. Engelshoven, and G. B. C. Vasbinder, “Contemporary imaging techniques for the diagnosis of renal artery stenosis,” European Radiology, vol. 15, no. 11, pp. 2219–2229, 2005. [168] ASTRAL Investigators, “Revascularization versus medical therapy for renal artery stenosis,” New England Journal of Medicine, vol. 361, pp. 1953–1962, 2009. [169] C. J. Cooper, T. P. Murphy, A. Matsumoto et al., “Stent revas- cularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial,” American Heart Journal, vol. 152, no. 1, pp. 59–66, 2006. [170] J. J. Caro, M. Salas, J. L. Speckman, G. Raggio, and J. D. Jackson, “Persistence with treatment for hypertension in actual practice,” Canadian Medical Association Journal, vol. 160, no. 1, pp. 31–37, 1999. 15 [171] G. Mazzaglia, L. G. Mantovani, M. C. J. M. Sturkenboom et al., “Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care,” Journal of Hypertension, vol. 23, no. 11, pp. 2093–2100, 2005. [172] B. L. G. van Wijk, O. H. Klungel, E. R. Heerdink, and A. de Boer, “Rate and determinants of 10-year persistence with antihypertensive drugs,” Journal of Hypertension, vol. 23, no. 11, pp. 2101–2107, 2005. [173] B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, and M. Burnier, “Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories,” British Medical Journal, vol. 336, no. 7653, pp. 1114–1117, 2008. [174] G. Corrao, A. Zambon, A. Parodi et al., “Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy,” Journal of Hypertension, vol. 26, no. 4, pp. 819–824, 2008. [175] P. R. Conlin, W. C. Gerth, J. Fox, J. B. Roehm, and S. J. Boccuzzi, “Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes,” Clinical Therapeutics, vol. 23, no. 12, pp. 1999–2010, 2001. [176] W. A. de Souza, M. Sabha, F. de Faveri Favero, G. Bergsten- Mendes, J. C. Yugar-Toledo, and H. Moreno, “Intensive monitoring of adherence to treatment helps to identify ”true” resistant hypertension,” Journal of Clinical Hypertension, vol. 11, no. 4, pp. 183–191, 2009. [177] J. Park and V. Campese, “Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis,” Journal of Clinical Hypertension, vol. 9, no. 1, pp. 7–12, 2007. [178] D. J. Hyman and V. N. Pavlik, “Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine,” Archives of Internal Medicine, vol. 160, no. 15, pp. 2281–2286, 2000. [179] S. A. Oliveria, P. Lapuerta, B. D. McCarthy, G. J. L’Italien, D. R. Berlowitz, and S. M. Asch, “Physician-related barriers to the eﬀective management of uncontrolled hypertension,” Archives of Internal Medicine, vol. 162, no. 4, pp. 413–420, 2002. [180] C. L. Trewet and M. E. Ernst, “Resistant hypertension: identifying causes and optimizing treatment regimens,” Southern Medical Journal, vol. 101, no. 2, pp. 166–173, 2008. [181] L. S. Phillips, W. T. Branch, C. B. Cook et al., “Clinical inertia,” Annals of Internal Medicine, vol. 135, no. 9, pp. 825–834, 2001. [182] E. M. Furmaga, F. E. Cunningham, W. C. Cushman et al., “National utilization of antihypertensive medications from 2000–2006 in the Veterans Health Administration: focus on thiazides diuretics,” Journal of Clinical Hypertension, vol. 10, pp. 770–778, 2008. [183] B. M. Egan, Y. Zhao, and R. N. Axon, “US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008,” Journal of the American Medical Association, vol. 303, no. 20, pp. 2043–2050, 2010. [184] E. Falaschetti, M. Chaudhury, J. Mindell, and N. Poulter, “Continued improvement in hypertension management in England: results from the health survey for England 2006,” Hypertension, vol. 53, no. 3, pp. 480–486, 2009. [185] N. H. McInnis, G. Fodor, M. Moy Lum-Kwong, and F. H. H. Leenen, “Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey